OpenLB
Open Library of Bioscience
Advanced Search
Cancer letters
Jan 28, 2014;342 (2): 170-7.

Epigenetic biomarkers in skin cancer.

Edward S Greenberg, Kelly K Chong, Kelly T Huynh, Ryo Tanaka, Dave S B Hoon
Author Information
  1. Edward S Greenberg: Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA.
PMID: 22289720 DOI: 10.1016/j.canlet.2012.01.020

Abstract

Epigenetic aberrations have been associated with cutaneous melanoma tumorigenesis and progression including dysregulated DNA gene promoter region methylation, histone modification, and microRNA. Several of these major epigenetic aberrations have been developed into biomarkers. Epigenetic biomarkers can be detected in tissue and in blood as circulating DNA in melanoma patients. There is strong evidence that biomarkers in cutaneous melanoma will have an important role as companions to therapeutics and overall patient management. Important progress has been made in epigenetic melanoma biomarker development and verification of clinical utility, and this review discusses some of the key current developments and existing challenges.

Keywords

BC BCC BM Biomarker CAE CIMP CTC CTCL ChIP CoBRA CpG island methylator phenotype DNA methyltransferase DNMT Epigenetics IHC LINE-1 MCC MINT MSP Melanoma Methylation MicroRNA OS PCR Prognosis ROC SBM SCC TMZ TRG UTR basal cell carcinoma biochemotherapy biomarker capillary array electrophoresis cell-free circulating nucleic acid cf-CNA chromatin immunoprecipitation circulating tumor cell combined bisulfite restriction analysis cutaneous T-cell lymphoma immunohistochemistry long interspersed nuclear element-1 merkel cell carcinoma methylated-in-tumor methylation-specific realtime PCR miRNA micro-RNAs overall survival polymerase chain reaction receiver operating characteristics sodium bisulfite modification squamous cell carcinoma temozolomide tumor-related genes untranslated region

References

  1. Br J Cancer. 2009 Aug 18;101(4):551-6 [PMID: 19638982]
  2. J Natl Cancer Inst. 2011 Aug 17;103(16):1227-35 [PMID: 21693730]
  3. Anal Chim Acta. 2011 Aug 12;699(2):134-52 [PMID: 21704768]
  4. Epigenetics. 2011 Mar;6(3):388-94 [PMID: 21081840]
  5. Cancer Res. 2010 May 15;70(10):4163-73 [PMID: 20442294]
  6. J Clin Oncol. 2005 Jun 10;23(17):3886-96 [PMID: 15897551]
  7. Cell. 2007 Feb 23;128(4):693-705 [PMID: 17320507]
  8. Arch Dermatol. 2011 Apr;147(4):443-9 [PMID: 21173302]
  9. Nat Rev Genet. 2002 Jun;3(6):415-28 [PMID: 12042769]
  10. J Clin Oncol. 2008 May 10;26(14):2299-304 [PMID: 18467721]
  11. J Invest Dermatol. 2010 Jan;130(1):221-9 [PMID: 19587692]
  12. F1000 Biol Rep. 2011;3:9 [PMID: 21655338]
  13. J Invest Dermatol. 2010 Apr;130(4):1116-25 [PMID: 19759548]
  14. Clin Chem. 2009 Apr;55(4):611-22 [PMID: 19246619]
  15. Br J Dermatol. 2006 Dec;155(6):1154-8 [PMID: 17107382]
  16. PLoS One. 2011;6(10):e26015 [PMID: 22046253]
  17. J Surg Oncol. 2011 May 1;103(6):508-17 [PMID: 21480243]
  18. Ann Surg. 2010 Mar;251(3):499-505 [PMID: 20134314]
  19. Cancer. 2006 Apr 1;106(7):1467-79 [PMID: 16518809]
  20. Nat Rev Genet. 2010 Mar;11(3):191-203 [PMID: 20125086]
  21. Clin Cancer Res. 2009 May 1;15(9):2988-94 [PMID: 19336521]
  22. Nat Rev Cancer. 2011 Jun;11(6):426-37 [PMID: 21562580]
  23. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [PMID: 10411935]
  24. Oncogene. 2012 Mar 22;31(12):1558-70 [PMID: 21860416]
  25. J Biol Chem. 2011 May 13;286(19):16606-14 [PMID: 21454583]
  26. J Cancer. 2011 Feb 24;2:116-22 [PMID: 21479130]
  27. Mol Cancer Res. 2011 Apr;9(4):418-29 [PMID: 21383005]
  28. Annu Rev Cell Dev Biol. 2002;18:495-513 [PMID: 12142272]
  29. Cancer Res. 2006 Jun 15;66(12):6111-7 [PMID: 16778184]
  30. Cancer Control. 2009 Jul;16(3):200-18 [PMID: 19556960]
  31. Cancer Res. 2010 May 15;70(10):3870-6 [PMID: 20406990]
  32. Genes Cancer. 2010 Nov;1(11):1100-14 [PMID: 21533017]
  33. Pigment Cell Melanoma Res. 2009 Feb;22(1):14-29 [PMID: 19040501]
  34. Cancer Cell. 2011 Jul 12;20(1):104-18 [PMID: 21741600]
  35. J Natl Cancer Inst. 2004 Jan 21;96(2):152-6 [PMID: 14734706]
  36. Transl Oncol. 2010 Apr;3(2):109-13 [PMID: 20360935]
  37. Clinics (Sao Paulo). 2011;66(10):1817-23 [PMID: 22012057]
  38. Oncogene. 2004 May 13;23(22):4014-22 [PMID: 15064737]
  39. J Proteomics. 2011 Jun 10;74(7):1002-14 [PMID: 21549228]
  40. Exp Gerontol. 2010 Apr;45(4):279-85 [PMID: 19818845]
  41. Clin Chem. 2011 Jan;57(1):84-91 [PMID: 21036945]
  42. Cancer Res. 2006 Jul 1;66(13):6692-8 [PMID: 16818643]
  43. Biochemistry. 2002 May 14;41(19):5945-9 [PMID: 11993987]
  44. Cancer Res. 2008 Apr 15;68(8):2745-54 [PMID: 18417445]
  45. Cell. 2007 Feb 23;128(4):683-92 [PMID: 17320506]
  46. Cancer Res. 2006 Aug 1;66(15):7390-4 [PMID: 16885332]
  47. Br J Haematol. 2008 May;141(5):672-5 [PMID: 18318758]
  48. Methods Mol Biol. 2011;791:1-10 [PMID: 21913067]
  49. J Am Coll Surg. 2007 Sep;205(3):453-62 [PMID: 17765162]
  50. J Invest Dermatol. 2008 Jul;128(7):1788-96 [PMID: 18219279]
  51. Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10 [PMID: 17890317]
  52. PLoS One. 2011;6(9):e24922 [PMID: 21949788]
  53. Cancer Res. 2002 Nov 1;62(21):6231-9 [PMID: 12414652]
  54. J Surg Oncol. 2011 Sep;104(4):438-46 [PMID: 21557225]
  55. EMBO J. 2011 May 18;30(10):1990-2007 [PMID: 21468029]
  56. Clin Cancer Res. 2009 Mar 1;15(5):1801-7 [PMID: 19223509]
  57. PLoS One. 2011 Apr 25;6(4):e18936 [PMID: 21541354]
  58. J Clin Oncol. 2000 Jan;18(1):158-66 [PMID: 10623706]
  59. FEBS Lett. 2011 Aug 4;585(15):2467-76 [PMID: 21723283]
  60. J Clin Oncol. 2006 Jan 10;24(2):268-73 [PMID: 16330673]
  61. Br J Cancer. 2011 Sep 27;105(7):1023-9 [PMID: 21863027]
  62. Blood. 2009 May 21;113(21):5064-73 [PMID: 19279331]
  63. J Transl Med. 2011 May 26;9:78 [PMID: 21615918]
  64. Methods Mol Biol. 2010;620:243-65 [PMID: 20652507]
  65. Methods. 2010 Apr;50(4):298-301 [PMID: 20146939]
  66. Ochsner J. 2010 Summer;10(2):83-92 [PMID: 21603362]
  67. Exp Dermatol. 2010 Oct;19(10):926-8 [PMID: 20849535]
  68. Yonsei Med J. 2009 Aug 31;50(4):455-63 [PMID: 19718392]
  69. Cell Res. 2008 Oct;18(10):997-1006 [PMID: 18766170]
  70. Mol Carcinog. 2009 Oct;48(10):903-9 [PMID: 19326371]
  71. APMIS. 2007 Oct;115(10):1161-76 [PMID: 18042149]
  72. Gut. 2009 Oct;58(10):1375-81 [PMID: 19201770]
  73. Melanoma Res. 2008 Aug;18(4):274-8 [PMID: 18626312]
  74. J Dermatol Sci. 2011 Mar;61(3):187-93 [PMID: 21273047]
  75. Nat Clin Pract Oncol. 2005 Aug;2(8):416-22 [PMID: 16130938]
  76. J Clin Oncol. 2005 Dec 20;23(36):9351-8 [PMID: 16361635]
  77. Cancer Res. 2009 Jan 15;69(2):449-57 [PMID: 19147557]
  78. Pigment Cell Melanoma Res. 2010 Oct;23(5):620-6 [PMID: 20557479]
  79. J Clin Oncol. 2009 Dec 20;27(36):6199-206 [PMID: 19917835]
  80. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61 [PMID: 18768788]
  81. Melanoma Res. 2010 Aug;20(4):253-65 [PMID: 20418788]
  82. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 [PMID: 18663219]
  83. Semin Oncol. 2005 Oct;32(5):479-87 [PMID: 16210089]
  84. RNA. 2010 May;16(5):991-1006 [PMID: 20360395]
  85. PLoS One. 2008;3(11):e3694 [PMID: 19002258]
  86. Nat Rev Cancer. 2006 Nov;6(11):857-66 [PMID: 17060945]
  87. Pigment Cell Res. 2007 Apr;20(2):92-111 [PMID: 17371436]
  88. Melanoma Res. 2004 Jun;14(3):173-81 [PMID: 15179185]
  89. J Transl Med. 2010 Jun 11;8:56 [PMID: 20540720]
  90. Proc Natl Acad Sci U S A. 2004 May 11;101(19):7357-62 [PMID: 15123803]
  91. BJU Int. 2012 Mar;109(5):660-4 [PMID: 21895937]
  92. Mol Cell Proteomics. 2006 Mar;5(3):541-52 [PMID: 16319397]

Grants

  1. P01 CA012582/NCI NIH HHS
  2. P01 CA012582-35S1/NCI NIH HHS
  3. P01 CA029605/NCI NIH HHS
  4. P01 CA029605-30/NCI NIH HHS

MeSH Term

Animals
Biomarkers, Tumor
DNA Methylation
Epigenesis, Genetic
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Genetic Testing
Histones
Humans
Melanoma
MicroRNAs
Phenotype
Predictive Value of Tests
Prognosis
Skin Neoplasms

Chemicals

Biomarkers, Tumor
Histones
MicroRNAs
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 10

Word Cloud

Created with Highcharts 10.0.0melanomabiomarkerscellEpigeneticcutaneousDNAcirculatingcarcinomaaberrationsregionmodificationepigeneticoverallbiomarkerPCRbisulfiteassociatedtumorigenesisprogressionincludingdysregulatedgenepromotermethylationhistonemicroRNASeveralmajordevelopedcandetectedtissuebloodpatientsstrongevidencewillimportantrolecompanionstherapeuticspatientmanagementImportantprogressmadedevelopmentverificationclinicalutilityreviewdiscusseskeycurrentdevelopmentsexistingchallengesskincancerBCBCCBMBiomarkerCAECIMPCTCCTCLChIPCoBRACpGislandmethylatorphenotypemethyltransferaseDNMTEpigeneticsIHCLINE-1MCCMINTMSPMelanomaMethylationMicroRNAOSPrognosisROCSBMSCCTMZTRGUTRbasalbiochemotherapycapillaryarrayelectrophoresiscell-freenucleicacidcf-CNAchromatinimmunoprecipitationtumorcombinedrestrictionanalysisT-celllymphomaimmunohistochemistrylonginterspersednuclearelement-1merkelmethylated-in-tumormethylation-specificrealtimemiRNAmicro-RNAssurvivalpolymerasechainreactionreceiveroperatingcharacteristicssodiumsquamoustemozolomidetumor-relatedgenesuntranslated

Similar Articles

Cited By